

Intellectual Property Prospector

IP Assets Owned by Firms in Transition

December 11, 2006
 Volume 1, Number 11
 Prospector Profiles in this Issue

Company Name	Reference Number	Category Profile
Acura Pharmaceutical	06.0249	Loss/Deficit
Aksys Limited	06.0250	Loss/Deficit
Assured Pharmacy, Inc.	06.0251	Loss/Deficit
Avani International Group Inc.	06.0252	Loss/Deficit
Axcess International, Inc.	06.0253	Loss/Deficit
BioForce Nanosciences, Inc.	06.0254	Loss/Deficit
Communication Intelligence Corp.	06.0255	Loss/Deficit
Diasys Corporation	06.0256	Audit Concerns
Digital Descriptor Systems, Inc.	06.0257	Loss/Deficit
Direct Insite Corp.	06.0258	Loss/Deficit
Eagle Broadband, Incorporated	06.0259	Audit Concerns
Electric Aquagenics Unlimited, Inc.	06.0260	Loss/Deficit
GVI Security Solutions, Inc.	06.0261	Loss/Deficit
Innuity, Inc.	06.0262	Loss/Deficit
IPIX Corp.	06.0263	Section 363 Sales
Life Sciences Research, Inc.	06.0264	Loss/Deficit
Lifestream Technologies, Inc.	06.0265	Bankruptcy
Metrologic Instruments, Inc.	06.0266	Low Rating
Micro Component Technology, Inc.	06.0267	Loss/Deficit
Nanobac Pharmaceuticals, Incorporated	06.0268	Loss/Deficit
PCS Edventures!.com, Inc.	06.0269	Loss/Deficit
PubliCARD, Inc.	06.0270	Loss/Deficit
Tm Bioscience Corp.	06.0271	Loss/Deficit
Unigene Laboratories, Inc.	06.0272	Loss/Deficit
World Heart Corp.	06.0273	Loss/Deficit
Zim Corporation	06.0274	Loss/Deficit

(Click on Reference Number to go directly to Company Profile)

Intellectual Property Prospector identifies United States and Canadian companies with more than \$1 million in assets filing for bankruptcy or reporting other financial difficulty and profiles their ownership of intellectual property. The Prospector features companies that meet strictly defined, predetermined criteria and is designed to support the efforts of firms and individuals interested in identifying opportunities in the specific area of intellectual property, which includes patents, trademarks, trade secrets, and licenses, among others. Information is compiled weekly and the Prospector is distributed by email every Sunday evening to arrive before 9:00AM every Monday. The Prospector is published by Beard Group, Inc. (<http://BeardGroup.com>). For subscription information call Customer Service at 240-629-3300, ext. 27.

Prospector Profile Selection Criteria:

In order to appear in the **Intellectual Property Prospector**, a company must report ownership of intellectual property assets, as well as one of the conditions listed below:

- An event which indicates financial distress; e.g., default, distressed exchange offer, preferred dividend omission, debt at deep discount, restructuring, low rating, audit concerns, covenant problems, and loss/deficit.
- Chapter 11, 7, or 15 bankruptcy filing
- Section 363 Sales

DISCLAIMER: The conditions for inclusion in the Prospector are selected by the editors, because, in their opinion, the occurrence of such an event or the existence of such a circumstance is a likely indicator of current or prospective financial or operating difficulty. There are, however, other reasons why such facts or circumstances may exist. The inclusion of a profile suggests the possibility of financial distress or the possibility that the company may be of interest to firms and individuals interested in identifying intellectual property for some other reason. *Inclusion should not be construed to represent analysis of the condition of the company or its intellectual property or a definitive determination that the company is in difficulty.*

ACCURACY & COVERAGE: The information contained herein is obtained from sources believed to be reliable. However, the accuracy of most data cannot be verified prior to publication, and the information is not guaranteed. Desired information is often incomplete, inaccurate, delayed or unavailable. Do not rely on the Prospector without independent verification.

SUBSCRIPTIONS: Subscription rate: \$575 for six months, payable in advance. All subscriptions entered are continued until canceled. For subscription information call Customer Service at (240) 629-3300, ext. 27.

Intellectual Property Prospector is a publication of **Beard Group, Inc.**, P. O. Box 4250, Frederick, MD 21705, (240) 629-3300, <http://www.beardgroup.com>. ISSN #to be determined. Copyright 2006. All rights reserved. Publisher: Christopher Beard.

**Prospector
Profile
06.0249**

Acura Pharmaceutical

616 N North Ct
Palatine, IL 60067
(847) 705-7709

NAICS		325412
Employees		13
Revenue	(mil)	\$0.00
Income	(mil)	(\$12.08)
Assets	(mil)	\$1.79
Liability	(mil)	\$7.95

(for the year ended 12/31/2005)

Category: Loss/Deficit

Event: Acura Pharmaceuticals Inc. reported a \$3,097,000 net loss on zero revenues for the quarterly period ended Sept. 30, 2006, against \$1,635,000 of net loss on zero revenues for the same period in 2005. Historically, the Company has incurred significant losses and until the time as its product candidates are commercialized, the Company is expected to continue incurring losses. At Sept. 30, 2006, the Company's balance sheet showed \$1,671,000 in total assets, \$11,935,000 in total liabilities, and \$10,264,000 in stockholders' equity deficit. The Company's September 30 balance sheet also showed strained liquidity with \$470,000 in total current assets available to pay \$11,922,000 in total current liabilities.

Intellectual Property: Aversion®, Axiom Pharmaceutical Corporation, and Acura Pharmaceuticals, are registered trademarks of Acura Pharmaceuticals, Inc. The Company has three US non-provisional and two international patent applications pending relating to its Aversion® Technology. Additionally, the Company has six US patents issued and three US patent applications pending related to its Opioid Synthesis Technologies. The Company retained ownership of all issued patents, patent applications, other intellectual property and commercial rights to its product candidates and its Aversion® Technology and Opioid Synthesis Technology. [SEC Filing 10-KSB 02-21-06]

Description: Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on research and development of an innovative and proprietary abuse deterrent, abuse resistant and tamper resistant platform technology (the "Aversion® Technology") designed to discourage abuse of orally administered pharmaceutical products.

Officers: Andrew D. Reddick (Pres., CEO, Dir.); Ron J. Spivey, Ph.D. (SVP & CSO); Peter A. Clemens, CPA (SVP, CFO & Sec.); James F. Emigh, R.Ph. (VP-Mktg. & Admin); Robert A. Seiser, CPA (VP, Treas. & Corp. Controller)

Auditor: BDO Seidman, LLP

Securities: Common Stock-Symbol ACUR.OB.;
330,564,049 common shares outstanding as of November 2, 2006.

[Return to top](#)

**Prospector
Profile
06.0250**

Aksys Limited

Two Marriott Drive
Lincolnshire, IL 60069
(847) 229-2020

NAICS		334510
Employees		87
Revenue	(mil)	\$2.67
Income	(mil)	(\$35.00)
Assets	(mil)	\$19.16
Liability	(mil)	\$22.46
(for the year ended 12/31/2005)		

Category: Loss/Deficit

Event: Aksys Limited's total stockholders' deficit increased by \$31.5 million to \$34.8 million as of Sept. 30, 2006, from \$3,304,723 as of Dec. 31, 2005. The Company's balance sheet at Sept. 30, 2006, showed \$6.9 million in total assets and \$41.8 million in total liabilities, compared to its Dec. 31, 2005 balance sheet, which showed \$19.1 million in total assets and \$22.4 million in total liabilities. The company's Sept. 30 balance sheet further showed negative working capital with \$5,008,044 in total current assets available to pay \$24,136,487 in total current liabilities. For the three months ended Sept. 30, 2006, the company incurred a \$6,301,267 net loss on \$431,265 of total revenues versus a \$7,018,225 net loss on \$822,309 of total revenues for the same period in 2005.

Intellectual Property: As of March 20, 2006, the Company owns or has rights in relevant fields to 47 U.S. patents and 26 foreign patents for technologies that are important to developing a safe, convenient, self-contained hemodialysis system. The Company has one additional patent application pending in the United States, and has additional patent applications pending in several other countries that have significant hemodialysis markets. The Company expects to file additional patent applications with respect to the PHD System as new technology is developed. [SEC Filing 10-K 04-14-06]

Description: The Company was formed to provide hemodialysis products and services for patients suffering from renal failure.

Officers: Leslie L. Lake (Chair); Howard J. Lewin (Pres. & CEO); Karen R. Krumeich (CFO); Rodney S. Kenley (SVP-Prod. Dev't.); Thomas F. Scully (SVP-Mfg.); Douglass B. Given MD, PhD (Dir.); Timothy M. Mayleben (Dir.); Rosemary Mazanet MD, PhD (Dir.); Gretchen C. Piller (Dir.)

Auditor: KPMG LLP

Securities: Common Stock-Symbol AKSY.PK; PNK;
32,177,574 common shares outstanding as of March 20, 2006.

[Return to top](#)

**Prospector
Profile
06.0251**

Assured Pharmacy, Inc.

17935 Sky Park Circle, Suite F
Irvine, CA 92614
(949) 222-9971

NAICS		325412
Employees		19
Revenue	(mil)	\$3.84
Income	(mil)	(\$4.80)
Assets	(mil)	\$1.62
Liability	(mil)	\$2.42
(for the year ended 12/31/2005)		

Category: Loss/Deficit

Event: Assured Pharmacy, Inc. 's balance sheet showed \$2,536,636 in total assets, \$2,826,817 in total current liabilities, and \$549,505 in total minority interest, resulting in an \$839,686 stockholders' deficit. The Company's stockholders' deficit at June 30, 2006, stood at \$177,763. For the third quarter ended Sept. 30, 2006, Assured Pharmacy reported a \$981,085 net loss on \$2,310,248 of sales compared with a \$2,835,877 net loss on \$980,181 of sales in the comparable quarter of 2005.

Intellectual Property: On March 15, 2004, the Company entered into a technology license agreement with Network Technology, Inc. (RxNT). The Technology License grants the Company the right to use RxNT's e-prescribing technology under the brand name "Assured Script." On November 9, 2004, the Company received trademark approval by the United States Patent and Trademark Office for the "eRXSYS" company logo. The Company changed its name to Assured Pharmacy, Inc. in October 2005 and no longer utilizes the trademarked "eRXSYS" logo. [SEC Filing 10-KSB 03-31-06]

Description: Assured Pharmacy, Inc. operates pharmacies that focus on dispensing pain medication in the United States. Its pharmacies utilize technology that enables physicians to transmit prescriptions from a wireless hand-held device or desktop computer directly to its pharmacies.

Officers: Robert DelVecchio (CEO & CFO); Haresh Sheth (COO)

Auditor: Squar, Milner, Reehl & Williamson, LLP

Securities: Common Stock-Symbol APHY.OB;
44,665,740 common shares outstanding as of March 16, 2006.

[Return to top](#)

**Prospector
Profile
06.0252**

Avani International Group Inc.

17 Fawcett Road, # 328
Coquitlam, Canada V3K 6V2
(604) 525-2386

NAICS		312112
Employees		7
Revenue	(mil)	\$0.31
Income	(mil)	\$0.07
Assets	(mil)	\$0.29
Liability	(mil)	\$1.26
(for the year ended 12/31/2005)		

Category: Loss/Deficit

Event: Avani International Group Inc. reported an \$88,618 net loss for the third quarter of 2006, compared with a \$756,491 net loss on \$20,391 of revenues for the same period in 2005. At Sept. 30, 2006, the company's balance sheet showed \$1,068,759 in total assets and \$1,289,470 in total liabilities, resulting in a \$220,711 stockholders' deficit. Accumulated deficit at Sept. 30, 2006, stood at \$7,962,299, as the company continues to experience significant losses from operations.

Intellectual Property: The Company has not sought patent protection for its proprietary oxygen enrichment process, rather, it relies, to the extent it can, upon trade secrets to protect its proprietary process. [SEC Filing 10-KSB 04-12-06]

Description: Avani International Group Inc. used to produce, market, and sell purified, oxygen enriched water under the brand name Avani Water.

Officers: Robert Wang (Pres. & Dir.); Dennis Robinson (Sec., Treas. & Dir.); Jeffrey Lightfoot (Dir.)

Auditor: Jeffrey Tsang & Co.

Securities: Common Stock-Symbol AVIT.OB; OTC BB;
14,582,571 common shares outstanding as of April 1, 2006.

[Return to top](#)

**Prospector
Profile
06.0253**

Access International, Inc.

3208 Commander Drive
Carrollton, TX 75006
(972) 407-6080

NAICS		561621
Employees		17
Revenue	(mil)	\$1.08
Income	(mil)	(\$3.26)
Assets	(mil)	\$0.93
Liability	(mil)	\$5.52

(for the year ended 12/31/2005)

Category: Loss/Deficit

Event: Access International, Inc. reported an \$873,608 net loss on \$369,621 of sales for the three months ended Sept. 30, 2006, compared with a \$785,720 net loss on \$204,711 of sales in the comparable period of 2005. At Sept. 30, 2006, the company's balance sheet showed \$1,258,707 in total assets and \$4,685,878 in total liabilities, resulting in \$3,427,171 stockholders' deficit. The Company's September 30 balance sheet also showed strained liquidity with \$1,023,732 in total current assets available to pay \$1,320,378 in total current liabilities coming due within the next 12 months.

Intellectual Property: The Company relies on a combination of patents, trade secrets, technology licenses, and other intellectual property rights. In total, the Company has received 16 U.S. patents with international coverage around the globe. During 2006, the Company sold 11 of the video patents. However, it still maintains a royalty free license to use the patents. The Company still has 5 patents and also has 4 patents in various stages of prosecution. The Company has applied for registration of a number of trade and service marks, including Access Inc.™ the Access Inc. (logo)™ LANcam, ActiveTag™, onlineaccess.com™, Prism Video™ and LANcorder™. [SEC Filing 10-KSB 03-30-06]

Description: AXCESS International, Inc. manufactures physical security and enterprise asset management systems that locate, identify, track, monitor, count, and protect people, property, and vehicles.

Officers: Richard C.E. Morgan (Chair); Allan Griebenow (Pres., CEO & Dir.); Allan L. Frank (VP, Sec. & CFO); Jim A. Ferguson (VP-Sales); Robert J. Bertoldi (Dir.); Paul J. Coleman, Jr. (Dir.); Robert F. Hussey (Dir.)

Auditor: Hein & Associates LLP

Securities: Common Stock-Symbol AXSI.OB; OTC BB;
27,437,111 common shares outstanding as of December 31, 2005.

[Return to top](#)

**Prospector
Profile
06.0254**

BioForce Nanosciences, Inc.

1615 Golden Aspen Drive, Suite 101
Ames, IA 50010
(515) 233-8333

NAICS		541710
Employees		12
Revenue	(mil)	\$0.00
Income	(mil)	(\$0.02)
Assets	(mil)	\$0.00
Liability	(mil)	\$0.04
(for the year ended 12/31/2005)		

Category: Loss/Deficit

Event: BioForce Nanosciences, Inc. incurred a net loss of \$623,096 for the three months ended Sept. 30, 2006, compared with a \$452,963 net loss for the three months ended Sept. 30, 2005. Revenue for 2006 was \$31,430, which is a \$3,426 decrease from fiscal 2005 sales of \$34,856. At Sept. 30, 2006, the company's balance sheet showed \$5,389,540 in total assets, \$620,955 in total liabilities and stockholders' equity of \$4,768,585.

Intellectual Property: The Company owns six core patents or patents pending and several other surrounding patents. Multiple patent applications related to these are pending in several countries. The Company has several trademarks or trademark applications pending or contemplated. These include: BioForce Nanosciences™, Smaller is Better™, NanoArrayer™, ViriChip™, NanoReader™, Chip-on-a-tip™, TipCleaner™, SPT™, Sindex™, MSP™, FemtoWare™, Practical Nanotechnology™. [SEC Filing 10-K 04-17-06]

Description: BioForce Nanosciences Holdings, Inc., a development stage company, provides commercial products for applications in nanotechnology.

Officers: Eric Henderson, Ph.D. (CEO & Chief Science Officer); Kerry Frey (COO & Dir.); Curtis Mosher, Ph.D. (VP-R&D); Jean-Jacques Sunier (Dir.); Larry Gold, Ph.D. (Dir.); Guenter H. Jaensche, Ph.D. (Dir.); Kerry Frey (Dir.)

Auditor: Moore & Associates Chartered

Securities: Common Stock-Symbol BFNH.OB; OTC BB;
24,000,000 common shares outstanding as of March 31, 2006.

[Return to top](#)

**Prospector
Profile
06.0255**

Communication Intelligence Corp.

275 Shoreline Drive
Redwood Shores, CA 94065-1413
(650) 802-7888

NAICS		423610
Employees		24
Revenue	(mil)	\$3.12
Income	(mil)	(\$4.03)
Assets	(mil)	\$8.47
Liability	(mil)	\$2.61
(for the year ended 12/31/2005)		

Category: Loss/Deficit

Event: Communication Intelligence Corporation reported a \$669,000 net loss on \$701,000 of revenues for the three months ended Sept. 30, 2006, versus a \$1,569,000 net loss on \$607,000 of revenues for the three months ended Sept. 30, 2005. At Sept. 30, 2006, the Company's balance sheet showed \$6,305,000 in total assets and \$2,157,000 in total liabilities resulting in a stockholders' equity of \$4,078,000.

Intellectual Property: CIC® and its logo, Handwriter®, Jot®, iSign®, InkSnap®, InkTools®, RecoEcho®, Sigo-On®, QuickNotes®, Sign-it®, WordComplete®, INKshrINK® and The Power To Sign Online® are registered trademarks of the Company. HRS', PenX', SignatureOne' and Speller' are trademarks of the Company. Applications for registration of various trademarks are pending in the United States, Europe and Asia. The Company relies on a combination of patents, copyrights, trademarks, trade secrets and contractual provisions to protect its software offerings and technologies. Over the years, the Company has developed and patented major elements of its software offerings and technologies. In addition, in October 2000 the Company acquired, from PenOp, Inc. and its subsidiary, a significant patent portfolio relevant to the markets in which the Company sells its products. [SEC Filing 10-KSB 03-30-06]

Description: The Group's principal activity is to develop, market and license security software and consumer electronics. The products of the Group include multi-lingual handwriting recognition systems and hand-writer recognition.

Officers: Jake Winebaum (Founder & CEO); Brian Barnum (CFO); Paul Dagum (Chief Scientist and Strategy Officer); Rob Feinstein (VP-Product); Ben Hanna (VP-Mktg.); Chris Hulse (VP-Sales & Business Dev't.); Alan Lang (VP-Eng'g.)

Auditor: Stonefield Josephson Inc.

Securities: Common Stock-Symbol CICI.OB;
106,542 common shares outstanding as of December 31, 2005.

[Return to top](#)

**Prospector
Profile
06.0256**

Diasys Corporation

21 West Main Street
Waterbury, CT 06702
(203) 755-5083

NAICS		334510
Employees		12
Revenue	(mil)	\$1.69
Income	(mil)	(\$1.05)
Assets	(mil)	\$2.47
Liability	(mil)	\$1.41

(for the year ended 6/30/2006)

Category: Audit Concerns

Event: Deloitte & Touche LLP expressed substantial doubt about DiaSys Corporation's ability to continue as a going concern after auditing the company's financial statements for the fiscal years ended June 30, 2006, and 2005. The auditing firm pointed to the company's recurring losses from operations, cash used by operating activities, negative working capital, and accumulated deficit.

Intellectual Property: The Company has been granted 20 patents on its R/S, FE, and Parasep technologies. Four patents have been issued both on the concept and specific architecture of the Company's workstation-systems. The Company has also been granted similar patent protection in Australia, Brazil, Canada, China, Switzerland, Germany, Spain, France, Great Britain, Greece, Italy, Japan, Portugal, and Singapore. The Company has additional applications for patents pending, both domestic and abroad. The Company has been granted trade name protection for "DiaSys" and these product names: Urizyme, DiaSys, Uriprep, Parasep, and Urisep. [SEC Filing 10-KSB 11-15-06]

Description: DiaSys Corporation engages in the design, development, manufacture, and distribution of workstation-instruments, consumables, reagents, and specialized test kits to hospital, clinical, and private physician laboratories worldwide.

Officers: Morris Silverman (Chair); Gregory Witchel (CEO & Dir.); Jeffrey B. Aaronson (Pres., CFO & Dir.); Robert M. Wigoda (Sec. & Dir.); Sherwin Gilbert (Dir.); Howard Bloom (Dir.); Sherman Lazrus (Dir.)

Auditor: Deloitte & Touche LLP

Securities: Common Stock-Symbol DYXC.OB; OTC BB;
21,372,864 common shares outstanding as of September 30, 2006.

[Return to top](#)

**Prospector
Profile
06.0257**

Digital Descriptor Systems, Inc.

2150 Highway 35
Sea Girt, NJ 08750
(732) 359-0260

NAICS		512191
Employees		20
Revenue	(mil)	\$3.34
Income	(mil)	(\$2.31)
Assets	(mil)	\$6.21
Liability	(mil)	\$14.92
(for the year ended 12/31/2005)		

Category: Loss/Deficit

Event: Digital Descriptor Systems, Inc. posted a \$291,791 net loss for the third quarter ended Sept. 30, 2006, compared with net income of \$644,282 for the three months ended Sept. 30, 2005. Revenues for the three months ended Sept. 30, 2006, were \$1,300,203, compared with \$1,118,922 for the three months ended Sept. 30, 2005, an increase of \$181,281 or 16%. The Company's balance sheet at Sept. 30, 2006, showed \$6,405,187 in total assets and \$19,048,314 in total liabilities, resulting in a \$12,643,127 stockholders' deficit.

Intellectual Property: The Company owns the proprietary rights to the software used in the Compu-Capture(R) programs. In addition, the Company owns the rights to the trademarks "Compu-Capture(R)", "Compu-Color(R)" and "Compu-Scan(R)", all trademarks have been registered with the United States Patent and Trademark Office. [SEC Filing 10-KSB 04-17-06]

Description: Digital Descriptor Systems, Inc. engages in the development, assembly, marketing, and installation of computer systems that capture video, digitally captured images, and scanned images; digitize the image; link the digitized images to text/data; and store the image and text on a computer database.

Officers: Anthony Shupin (Pres., CEO & Dir.); Michael Pellegrino (SVP, CFO & Dir.); Erik Hoffer (EVP & Dir.); Robert Gowell (Dir.); Vincent Moreno (Dir.)

Auditor: Bagell, Josephs, Levine & Company LLC

Securities: Common Stock-Symbol DDSI.PK; PNK;
5,454,943,898 common shares outstanding as of April 3, 2006.

[Return to top](#)

**Prospector
Profile
06.0258**

Direct Insite Corp.

80 Orville Drive
Bohemia, NY 11716
(631) 244-1500

NAICS		541511
Employees		57
Revenue	(mil)	\$8.87
Income	(mil)	(\$0.99)
Assets	(mil)	\$3.18
Liability	(mil)	\$6.92
(for the year ended 12/31/2006)		

Category: Loss/Deficit

Event: Direct Insite Corp. reported a \$93,000 net loss on \$2.2 million of revenues for the third quarter ended Sept. 30, 2006, compared with a \$128,000 net income on \$2.5 million of revenues for the same period in 2005. At Sept. 30, 2006, the company's balance sheet showed \$2.92 million in total assets and \$7.40 million in total liabilities, resulting in a \$4.48 million total stockholders' deficit. Additionally, accumulated deficit as of Sept. 30, 2006, stood at \$4.1 million.

Intellectual Property: The Company has two federally registered trademarks, which it relies upon: "dbExpress(TM)" and "dbACCEL(TM)". In addition, the Company received a patent for the proprietary aspects of its dbExpress technology in 1994, and a second, expanded patent on that technology in 1995, which broadened the claims regarding the product's graphical interface and indexing. The Company also relies on proprietary knowledge and employs various methods, including confidentiality agreements, to protect its software codes, concepts, ideas and documentation of its proprietary technology. [SEC Filing 10-KSB - 04-17-06]

Description: Direct Insite Corp. operates as an application service provider.

Officers: James Cannavino (Chair & CEO); Michael J. Beecher (CFO, Principal Acctg. Officer & Sec.); Arnold Leap (EVP & CTO); Matthew E. Oakes (EVP & COO)

Auditor: Marcum & Kliegman LLP

Securities: Common Stock-Symbol DIRI.OB;
4,933,028 common shares outstanding as of March 17, 2006.

[Return to top](#)

**Prospector
Profile
06.0259**

Eagle Broadband, Incorporated

101 Courageous Dr.
League City, TX 77573
(281) 538-6000

NAICS		237100
Employees		44
Revenue	(mil)	\$3.94
Income	(mil)	(\$26.93)
Assets	(mil)	\$21.76
Liability	(mil)	\$19.90
(for the year ended 8/31/2006)		

Category: Audit Concerns

Event: LBB & Associates LTD LLP raised substantial doubt about Eagle Broadband, Inc.'s ability to continue as a going concern. The Company has negative working capital of \$10,613,000 and has incurred losses of \$26,933,000 and \$57,010,000 during the years ended August 31, 2006 and 2005, respectively. The auditing firm said the Company will require additional working capital to develop its business and until it either achieves a level of revenues adequate to generate sufficient cash flows from operations or obtains additional financing necessary to support its working capital requirements. [SEC Filing 10-K 11-20-06]

Intellectual Property: The Company protects its proprietary technology through a combination of trade secrets, non-disclosure agreements, patent applications, copyright filings, trademarks, technical measures, and common law remedies with respect to its proprietary technology. The Company has received patents on its SatMAX and MediaPro set-top box products. [SEC Filing 10-K 11-20-06]

Description: Eagle Broadband, Incorporated is a provider of broadband Internet protocol and satellite communications technology and services.

Officers: David Micek (CEO & Dir.); Robert Bach (Dir.); Glenn Goerke (Dir.); Lorne Persons, Jr. (Dir.); C. J. Reinhartsen (Dir.); James Yarbrough (Dir.)

Auditor: Lopez, Blevins, Bork and Associates LLP

Securities: Common Stock-Symbol EAG; AMEX;
18,088,204 common shares outstanding as of November 10, 2006.
12% convertible note due February 10, 2011; 12% promissory note due July 24, 2008.

[Return to top](#)

**Prospector
Profile
06.0260**

Electric Aquagenics Unlimited, Inc.

1464 West 40 South, Suite 200
Lindon, UT 84042-1629
(801) 443-1031

NAICS		325412
Employees		43
Revenue	(mil)	\$0.67
Income	(mil)	(\$13.02)
Assets	(mil)	\$2.89
Liability	(mil)	\$8.55
(for the year ended 12/31/2005)		

Category: Loss/Deficit

Event: Electric Aquagenics Unlimited, Inc.'s balance sheet at Sept. 30, 2006, showed \$5,564,734 in total assets, \$8,470,534 in total liabilities, and \$2,905,800 in stockholders' deficit, as compared to total assets of \$5,809,927, total liabilities of \$8,546,598, and stockholders' deficit of \$2,736,671 at Dec. 31, 2005. The Company reported a \$1,351,852 net loss on \$778,737 of revenues for the quarterly period ended Sept. 30, 2006, as against a net loss of \$4,218,100 on \$278,767 of total revenues for the same period in 2005.

Intellectual Property: The names "Primacide A," "Primacide B," "Primacide C," "EAU," "Empowered Water," "Empowering Water," "Empowered Ice," EAU Technologies, Inc., "Electric Aquagenics Unlimited," "Aquagen," "Perfect Empowered Drinking Water," "Perfect Oxygenated Essentials," "Perfect Hand Protectant and Sanitizer," "Perfect Sports Drink," "Perfect Pre-Sports Drink," "Perfect Colon Cleanse," "Perfect Formula 116," "Perfect Foot Defense," and "Perfect Oxygenated Supplements" are some of the Company's trademarks. The Company has filed several provisional utility patent applications with the U.S. Patent and Trademark Office. Two patents have been issued while others are in pending or application status. The Company has entered into an exclusive license for certain stabilized acid water (Primacide C) technology developed by the University of Georgia. Two other patent applications that have been filed by the Company involves stabilizing its Primacide C product and a process application for poultry processing. [SEC Filing 10-KSB 04-17-06]

Description: Electric Aquagenics Unlimited, Inc., a/k/a EAU Technologies, Inc. is in the business of developing, manufacturing and marketing equipment that uses water electrolysis to create fluids.

Officers: Wade Bradley (Pres. & CEO); Doug Kindred (SVP-Mfg.); Larry Earle (SVP); Joseph A. Stapley (VP- Bus. Dev't.); Randall Waters (Gen. Mgr.)

Auditor: HJ & Associates

Securities: Common Stock-Symbol EAQU.OB; OTCBB;
9,417,580 common shares outstanding as of April 14, 2006.

[Return to top](#)

**Prospector
Profile
06.0261**

GVI Security Solutions, Inc.
2801 Trade Center Dr., Suite 120
Carrollton, TX 75007
(972) 245-7353

NAICS		561621
Employees		61
Revenue	(mil)	\$41.17
Income	(mil)	(\$13.02)
Assets	(mil)	\$25.23
Liability	(mil)	\$20.62
(for the year ended 12/31/2005)		

Category: Loss/Deficit

Event: On November 17, 2006, GVI Security Solutions, Inc. reported that its accumulated deficit increased to \$28,274,000 as of September 30, 2006, up from an accumulated deficit of \$18,284,000 as of December 31, 2005. As of September 30, 2006, the Company had \$12,505,000 in total assets and \$17,025,000 in total liabilities, resulting in \$4,520,000 stockholders' deficit. The Company incurred a net loss of \$2,994,000 on revenues of \$10,067,000 for the three months ended September 30, 2006.

Intellectual Property: Rapor, which was acquired by GVI Security Solutions in December 2004, is the owner of patent number 5,845,692 issued on December 8, 1998. The patent describes Rapor's Fast Trac™ portal as a Rapid Access Portal that utilizes a rapid access door system which allows authorized individuals passage through the doors and blocks the entry of unauthorized individuals, rerouting them to unsecured areas. The Company also has several pending trademark applications for "GVI" in connection with the products they sell. [SEC Filing 10-KSB 03-31-06]

Description: GVI Security Solutions, Inc., through its subsidiaries, provides video surveillance and security solutions to the homeland security, professional and business-to-business markets.

Officers: Steven Walin (CEO & Dir.); Joseph Restivo (CFO & Dir.); Craig Ellin (Dir.); Gary Freeman (Dir.); David Weiner (Dir.); Moshe Zarmi (Dir.)

Auditor: Mercadien PC

Securities: Common Stock-Symbol GVSS.OB;
OTC BB; 178,275,973 common shares outstanding as of November 13, 2006.

[Return to top](#)

**Prospector
Profile
06.0262**

Innuity, Inc.

8644 154th Avenue NE
Redmond, WA 98052
(425) 497-9909

NAICS		518111
Employees		176
Revenue	(mil)	\$12.45
Income	(mil)	(\$9.37)
Assets	(mil)	\$9.86
Liability	(mil)	\$12.45
(for the year ended 12/31/2005)		

Category: Loss/Deficit

Event: Innuity, Inc. reported a \$1.7 million net loss for the quarter ended Sept. 30, 2006, compared to a \$2.4 million net loss for the third quarter of 2005. The net loss for the third quarter of 2006 before non-cash items was \$525,000, an improvement of \$200,000, from a \$725,000 net loss before non-cash items during the second quarter of 2006. At Sept. 30, 2006, the Company's balance sheet showed \$7,049,864 in total assets and \$9,466,184 in total liabilities, resulting in a \$2,416,320 stockholders' deficit.

Intellectual Property: The Company relies on a combination of trademark, copyright and trade secret laws in the U.S. and other jurisdictions to protect its proprietary technology and its brand. The Company also enters into confidentiality and invention assignment agreements with employees and consultants, and confidentiality agreements with other third parties, and rigorously control access to its proprietary technology. The Company does not currently have any patents or pending patent applications. The Company has filed a U.S. federal trademark application for the following trademarks: Innuity; "Small is the new big"; and Innuity Velocity. Its unregistered trademarks include FreeStarter.com, Jadeon, Merchant Partners, Optify and 10x Marketing. [SEC Filing 10-KSB 03-23-06]

Description: Innuity, Inc., is an Internet technology company, engages in the design, acquisition, and integration of applications to deliver solutions for small business in the United States. Its Internet technology is based on an on-demand model that allows small businesses to interact with customers, business partners, and vendors.

Officers: John Wall (Chair & CEO); John Dennis (Pres.); Bob Bench (CFO); Marvin Mall (COO); Shivonne Byrne (CMO)

Auditor: Hansen, Barnett & Maxwell

Securities: Common Stock-Symbol INNU.OB; OTCBB;
19,846,372 common shares outstanding as of March 22, 2006.

[Return to top](#)

**Prospector
Profile
06.0263**

IPIX Corp.

12120 Sunset Hills Road, Suite 410
Reston, VA 20190
(703) 674-4100

NAICS		423410
Employees		34
Revenue	(mil)	\$5.40
Income	(mil)	(\$22.02)
Assets	(mil)	\$12.29
Liability	(mil)	\$5.95
(for the year ended 12/31/2005)		

Category: Section 363 Sales

Event: Donald F. King, the court-appointed Chapter 7 trustee of IPIX Corporation, disclosed two auctions to be held on December 12 and 20 regarding the Company's tangible assets and provisional patents for Gigapixel camera technology. Both will be held at the U.S. Bankruptcy Court for the Eastern District of Virginia, Alexandria Division, with motions to approve the sales to the highest bidders made immediately after the auctions' conclusions, according to Donald F. King, the court-appointed Chapter 7 trustee. The December 12 auction is focused on the sale of IPIX equipment and furniture. The assets will be sold in bulk and are physically housed in IPIX Reston and in storage facilities in Chantilly, Virginia, and Tennessee. The auction of the Gigapixel provisional patents is scheduled on Dec. 20.

Interested bidders may contact Stephen Karbelk at Tranzon Fox at Tel. No. (703) 539-8622.

Intellectual Property: IPIX currently has over 20 U.S. patents. Provisional patents have been filed on the Gigapixel camera being developed under the DARPA contract. In addition, it holds international counterparts to many U.S. patents in selected countries covering various aspects of products. IPIX has numerous patent applications pending in the United States as well as international counterparts to many of these applications. Finally, it has a non-exclusive and royalty-free license under numerous U.S. and foreign patents from Sarnoff Corporation and from Motorola, Inc. related to immersive imaging technologies and techniques. [SEC Filing 10-K 03-21-06]

Description: IPIX Corporation provides imaging solutions for commerce, communication, and security applications in the United States and internationally.

Officers: James O. Griffin (VP & Gen. Mgr.)

Auditor: PricewaterhouseCoopers LLP

Securities: Common Stock-Symbol IPIXQ.PK;
27,483,874 common shares outstanding as March 1, 2006.

[Return to top](#)

**Prospector
Profile
06.0264**

Life Sciences Research, Inc.

P.O. Box 2360, Mettlers Rd.
East Millstone, NJ 08875
(732) 649-9961

NAICS		541710
Employees		1,407
Revenue	(mil)	\$172.01
Income	(mil)	\$1.49
Assets	(mil)	\$184.37
Liability	(mil)	\$198.94
(for the year ended 12/31/2005)		

Category: Loss/Deficit

Event: On November 8, 2006, Life Sciences Research, Inc.'s balance sheet as of September 30, 2006, showed total assets of \$204.8 million and total liabilities of \$230.1 million, resulting in a total stockholders' deficit of \$25.3 million. As of December 31, 2005, the Company's total stockholders' deficit stood at \$14.5 million. For the third quarter ended September 30, 2006, the Company reported net income of \$2.6 million on revenues of \$49.4 million, compared with net income of \$1.1 million on revenues of \$43.7 million for the same quarter in the prior year.

Intellectual Property: The Company believes that its proprietary know-how plays an important role in the success of its business. Where the Company considers it appropriate, steps are taken to protect its know-how through confidentiality agreements and protection through registration of title or use. However the Company has no patents, trademarks, licenses, franchises or concessions which are material and upon which any of the services offered are dependent. [SEC Filing 10-K 03-16-06]

Description: Life Sciences Research, Inc., through its subsidiaries, operates as a contract research organization worldwide.

Officers: Andrew Baker (Chair & CEO); Brian Cass (Pres. & Dir.); Julian Griffiths (VP); Mark Bibi (Gen. Counsel & Sec); Richard Michaelson (CFO); Gabor Balthazar (Dir.); Afonso Junqueiras (Dir.); Yaya Sesay (Dir.)

Auditor: Hugh Scott PC

Securities: Common Stock-Symbol LSRI.PK; PNK;
12,675,120 common shares outstanding as of November 3, 2006.

[Return to top](#)

**Prospector
Profile
06.0265**

Lifestream Technologies, Inc.

570 Clearwater Loop, Building 1000
Post Falls, ID 83854
(208) 457-9409

NAICS		334510
Employees		11
Revenue	(mil)	\$2.11
Income	(mil)	(\$7.21)
Assets	(mil)	\$2.24
Liability	(mil)	\$8.63
(for the year ended 6/30/2005)		

Category: Bankruptcy

Event: Lifestream Technologies, Inc. filed for Chapter 11 protection on November 29, 2006 with the Bankruptcy Court for the District of Nevada (Las Vegas), case number 06-13589, Judge Bruce A. Markell presiding.

Intellectual Property: The Company owns various copyright registrations primarily related to the software used by its current and predecessor cholesterol monitors and its "Data Concern" Personal Health Smart Card. The Company owns various U.S. trademark registrations primarily related to the "Lifestream" names and logo designs, as well as the trade names of its various products such as "Cholestron", "The Data Concern", and "Personal Health Card". It also owns pending U.S. trademark applications for the following trademarks: Lifestream, Lifestream Technologies (and logo design), Know It for Life, Privalink, Personal Data Key, Personal Document Key, Personal Financial Key, and Personal Health Key. On October 1, 2005, the Company entered into a non-exclusive trademark license agreement with an unrelated company to utilize the trade name "Personal Health Card". [SEC Filing 10-KSB 10-12-05]

Description: Lifestream Technologies, Inc. engages in the development, manufacture, and marketing of a cholesterol monitor, and related supplies and accessories in the United States and the United Kingdom.

Officers: Christopher T. Maus(Chair, Pres. & CEO); Neil Luckianow (Dir.); Matt Colbert (VP-Fin.); Robert F. Boyle (Sec. & Dir.)

Auditor: BDO Seidman, LLP

Attorneys: James B. Macrobbie, Esq. of DLA Piper US LLP; Las Vegas, NV; (702) 677-3900

Securities: Common Stock-Symbol LFTC.PK;
264,374,983 common shares outstanding as of May 10, 2006.

Notes: Financial condition as of September 2006:
Total Assets: \$571,396 Total Debts: \$4,930,248

[Return to top](#)

**Prospector
Profile
06.0266**

Metrologic Instruments, Inc.

90 Coles Rd.
Blackwood, NJ 08012
(856) 228-8100

NAICS		561499
Employees		1,400
Revenue	(mil)	\$210.45
Income	(mil)	\$17.81
Assets	(mil)	\$226.18
Liability	(mil)	\$65.89
(for the year ended 12/31/2005)		

Category: Low Rating

Event: On November 27, 2006, Moody's Investors Service assigned a Caa1 rating to the proposed \$75 million second lien senior secured credit facility of Metrologic Instruments, Inc. The rating for the senior secured facility reflects both the overall probability of default of the Company, to which Moody's assigns a loss given default LGD 5 for the second lien. The rating outlook is stable.

Intellectual Property: The Company files domestic and foreign patent applications to protect its technological position and new product development. As of March 1, 2006, the Company owned 306 U.S. patents, which expire between 2006 and 2022, and 61 foreign patents, which expire between 2005 and 2019. In addition, the Company has 195 patent applications currently on file with the U.S. Patent and Trademark Office and foreign patent offices with respect to certain products and improvements it has developed. The Company owns numerous United States and foreign trademark registrations. It intends to continue to file applications for United States and foreign patents and trademarks. Although the Company believes that its patents provide a competitive advantage, it also relies upon its proprietary know-how, innovative skills, technical competence and marketing abilities. [SEC Filing 10-K 03-15-06]

Description: Metrologic Instruments, Inc., together with its subsidiaries, engages in the design, manufacture and marketing of bar code scanning and high-speed automated data capture solutions using laser, holographic and vision-based technologies.

Officers: C. Harry Knowles (Chair & Interim CEO); Mark Schmidt (EVP); Joseph Sawitsky (EVP); Janet H. Knowles (VP, Treas. & Dir.); Michael Coluzzi (CFO); Richard C. Close (Dir.); John H. Mathias (Dir.); Stanton L. Meltzer (Dir.); Hsu Jau Nan (Dir.); William Rulon-Miller (Dir.)

Auditor: Ernst & Young LLP

Securities: Common Stock-Symbol MTLG; NasdaqGS;
22,858,443 common shares outstanding as of October 31, 2006.

[Return to top](#)

**Prospector
Profile
06.0267**

Micro Component Technology, Inc.

2340 West County Road C
St Paul, MN 55113-2528
(651) 697-4000

NAICS		334413
Employees		80
Revenue	(mil)	\$7.07
Income	(mil)	(\$5.01)
Assets	(mil)	\$4.55
Liability	(mil)	\$11.60
(for the year ended 12/31/2006)		

Category: Loss/Deficit

Event: Micro Component Technology, Inc. posted a \$1.9 million net loss in the third quarter of 2006, compared to net loss of \$1 million in the comparable prior year period. The current quarter's net loss included \$1.4 million of non-cash debt conversion expense from the 10% subordinated convertible debt. The net loss for the nine-month period of 2006 was \$3 million, compared to a net loss of \$3.6 million in the prior year. At Sept. 30, 2006, the Company's balance sheet showed \$5,665,000 in total assets and \$10,785,000 in total liabilities, resulting in a \$5,120,000 stockholders' deficit.

Intellectual Property: The Company currently has four U.S. patents issued and active. In certain cases, the Company may also choose to keep an invention or process confidential as trade secrets, in lieu of making public disclosure through the patenting process. Key employees are required to enter into nondisclosure and invention assignment agreements, and customers, vendors and other third parties also must agree to nondisclosure restrictions prior to disclosure of its trade secrets or other confidential or proprietary information. The Company has developed and was using trademarks, slogans and other commercial symbols to advertise and sell its products, a number of which have been registered with the U.S. Patent and Trademark Office. The Company's proprietary computer programs are protected under federal copyright law as unpublished original works. It also maintains the secrecy of its software source codes through licensing and other restrictions. [SEC Filing 10-KSB 03-31-06]

Description: Micro Component Technology (MCT) is the world leader in semiconductor backend automation solutions. MCT is a foremost global provider of automated strip test handlers and factory automation software with over 12,000 handlers and testers installed worldwide.

Officers: Roger E. Grower (Chair, Pres. & CEO); BachThuy T. Vo (CFO); Donald J. Kramer (Dir.); David M. Sugishita (Dir.); Patrick Verderico (Dir.); Donald R. VanLuvanee (Dir.)

Auditor: Virchow, Krause & Company, LLP

Securities: Common Stock-Symbol MCTI.OB;
27,215,361 common shares outstanding as of March 15, 2006.

[Return to top](#)

**Prospector
Profile
06.0268**

Nanobac Pharmaceuticals, Incorporated

4730 North Habana Avenue, Suite 205
Tampa, FL 33614
(813) 264-2241

NAICS		541710
Employees		13
Revenue	(mil)	\$0.66
Income	(mil)	(\$3.69)
Assets	(mil)	\$8.97
Liability	(mil)	\$6.51

(for the year ended 12/31/2005)

Category: Loss/Deficit

Event: Nanobac Pharmaceuticals Inc.'s balance sheet as of Sept. 30, 2006, showed total assets of \$8,098,539 and total liabilities of \$8,426,496, resulting in a total stockholders' deficit of \$327,957. This compared to the company's \$2,464,721 stockholders' equity as of Dec. 31, 2005. The company's Sept. 30 balance sheet also showed strained liquidity with \$269,425 in total current assets available to pay \$5,589,958 in total current liabilities. For the three months ended Sept. 30, 2006, the company's net loss increased to \$787,183 from \$673,913 for the three months ended Sept. 30, 2005. Revenues for the current quarter decreased to \$23,894 from \$130,394 for the same period last year.

Intellectual Property: The Company has filed applications for a number of patents, has been granted patents, and awaits prosecution of pending application in the US and International Stages. Trade secret protection for unpatented confidential and proprietary information is also important to the Company. [SEC Filing 10-KSB 03-31-06]

Description: Nanobac Pharmaceuticals, Incorporated, a bio-lifescience company, engages in the research and development of therapeutic and diagnostic technologies related to nanobacterium sanguineum.

Officers: John Stanton (Chair, CEO & CFO); Alex Edwards (Dir.); Dr. Benedict Maniscalco (Dir.); Dr. Stephen Rechtschaffen (Dir.)

Auditor: Aidman, Piser & Company, P.A.

Securities: Common Stock-Symbol NNBP.OB; OTC BB;
193,506,760 common shares outstanding as of March 20, 2006.

[Return to top](#)

**Prospector
Profile
06.0269**

PCS Edventures!.com, Inc.

345 Bobwhite Court, Suite #200
Boise, ID 83706
(208) 343-3110

NAICS		610000
Employees		17
Revenue	(mil)	\$2.60
Income	(mil)	(\$1.21)
Assets	(mil)	\$1.76
Liability	(mil)	\$1.25

(for the year ended 3/31/2006)

Category: Loss/Deficit

Event: As of Sept. 30, 2006, PCS Edventures!.com, Inc. 's balance sheet showed \$1,315,129 in total assets and \$1,626,579 in total liabilities, resulting in a \$311,450 stockholders' deficit. The Company's September 30 balance sheet also showed a working capital deficit of \$1,158,867 with \$467,712 in total current assets available to pay \$1,626,579 in total current liabilities. The second fiscal quarter ended Sept. 30, 2006, resulted in a net loss of \$691,569, compared with the net loss for quarter ended Sept. 30, 2005, of \$140,216. Revenues for the three-month period ended Sept. 30, 2006, decreased to \$504,886 or by approximately 38%, as compared with \$811,437 for the three-month period ended Sept. 30, 2005.

Intellectual Property: The Company currently uses these trade names: PCS & Design(Registered), Academy of Learning(Trademarked), Edventures!(Trademarked), and PCS BrickLab!(Trademarked), PCS Academy of Science(Trademarked), PCS Edventures!.com, Inc.(Registered), WebLab(Trademarked), PCS STEPS & Design(Trademarked), Young Learning(Trademarked), and PCS Academy of Engineering(Trademarked). At the present time, the Company has not applied for any patents, and does not have any patents pending. [SEC Filing 10-KSB 06-29-06]

Description: PCS Edventures!.com, Inc. engages in the design, development, and marketing of educational learning labs bundled with related technologies and programs to the K-14 market worldwide.

Officers: Anthony A. Maher (Chair, Pres. & CEO); Robert O. Grover (EVP & CTO); Christina M. Vaughn (VP & CFO); Donald J. Farley (Sec.); Cecil D. Andrus (Dir.); Michael K. McMurray (Dir.)

Auditor: HJ & Associates, LLC

Securities: Common Stock-Symbol PCSV.OB; OTC BB; 27,088,855 common shares outstanding as of June 9, 2006.

[Return to top](#)

**Prospector
Profile
06.0270**

PubliCARD, Inc.

One Rockefeller Plaza, 14th Floor
New York, NY 10020
(212) 651-3102

NAICS		323119
Employees		31
Revenue	(mil)	\$3.62
Income	(mil)	(\$2.03)
Assets	(mil)	\$2.64
Liability	(mil)	\$9.79

(for the year ended 12/31/2005)

Category: Loss/Deficit

Event: PubliCARD Inc. reported a \$7,081,000 net income on \$887,000 of revenues for the quarter ended Sept. 30, 2006, compared with a \$312,000 net loss on \$1,029,000 of revenues for the same period in 2005. The increase in net income is primarily due to the company's recognition of a \$7.2 million gain on settlement of the liability to the Pension Benefit Guaranty Corp. At Sept. 30, 2006, the Company's balance sheet showed \$1,321,000 in total assets and \$2,341,000 in total liabilities, resulting in a \$1,020,000 total stockholders' deficit. The Company's balance sheet at Sept. 30, 2006, also showed strained liquidity with \$1,297,000 in total current assets available to pay \$2,122,000 in total current liabilities.

Intellectual Property: Infineer, PubliCARD's subsidiary, relies on a combination of copyright and trademark laws, trade secrets, confidentiality agreements and contractual provisions to protect its proprietary rights. Infineer seeks to protect its software, documentation and other written materials under trade secret and copyright laws, which afford only limited protection. Infineer generally enters into confidentiality and non-disclosure agreements with its employees and with key vendors and suppliers. [SEC Filing 10-K 03-31-06]

Description: PubliCARD, Inc., through its subsidiary, engages in the design and deployment of smart card solutions for educational and corporate sites.

Officers: Harry I. Freund (Chair); Jay S. Goldsmith (Vice Chair); Antonio L. DeLise (Pres., CEO, CFO & Sec.); Clifford B. Cohn (Dir.); L. G. Schafran (Dir.); Emil Vogel (Dir.)

Auditor: Deloitte & Touche LLP

Securities: Common Stock-Symbol CARD.OB; OTC BB;
24,940,902 common shares outstanding as of March 24, 2006.

[Return to top](#)

**Prospector
Profile
06.0271**

Tm Bioscience Corp.

439 University Ave., Suite 2000
Toronto, Ontario M5G 1Y8 Canada
(416) 593-4323

NAICS	621511
Employees	
Revenue (mil)	\$7.67
Income (mil)	(\$15.17)
Assets (mil)	\$30.86
Liability (mil)	\$18.54
(for the year ended 12/31/2005)	

Category: Loss/Deficit

Event: On November 17, 2006, Tm Bioscience Corp. had a net loss of \$5,645,628 on revenues of \$2,621,294 for the quarter ended September 30, 2006, up from a net loss of \$3,089,168 on revenues of \$2,207,652 for the quarter ended September 30, 2005. The Company's accumulated deficit as of September 30, 2006 increased to \$79,270,131 from an accumulated deficit of \$64,486,195 as of December 31, 2005. The Company's balance sheet as of September 30, 2006 showed stockholders' deficit of \$1,388,428 and strained liquidity with \$11,347,957 in total current assets available to pay \$17,012,833 in total current liabilities.

Intellectual Property: The Company has a number of patents issued and pending in the United States and Canada. The Company's intellectual property also includes trade secrets and technical know-how. The Company seeks to protect its trade secrets and technical know-how in part by confidentiality and non-disclosure agreements with its employees, consultants and strategic partners. [SEC Filing 10-K 09-29-06]

Description: Tm Bioscience Corp. is a DNA-based diagnostics company developing a suite of products focused in the fields of human genetic disorders, personalized medicine and infectious diseases.

Officers: Paul N. Lucas (Chair); Neil M. Reid (Vice Chair); Gregory C. Hines (Pres., CEO & Dir.); Daniel Kobler (VP); Alan Coley (VP); Jeremy Bridge-Cook (SVP); James E. Pelot (COO & CFO); Richard A. Janeczko (Chief Scientific Officer); John R. Frederick (Dir.); Michael Mueller (Dir.); Bradley Popovich (Dir.)

Auditor: Ernst & Young LLP

Securities: Common Stock-Symbol TMC.TO; Toronto Stock Exchange; 47,715,224 common shares outstanding as of September 30, 2006.

[Return to top](#)

**Prospector
Profile
06.0272**

Unigene Laboratories, Inc.

110 Little Falls Road
Fairfield, NJ 07004
(973) 882-0860

NAICS		541710
Employees		88
Revenue	(mil)	\$14.28
Income	(mil)	(\$0.50)
Assets	(mil)	\$12.77
Liability	(mil)	\$29.28
(for the year ended 12/31/2005)		

Category: Loss/Deficit

Event: Unigene Laboratories Inc.'s balance sheet at Sept. 30, 2006, showed \$16,108,404 in total assets and \$27,514,927 in total liabilities, resulting in an \$11,406,523 stockholders' deficit. The Company's deficit at Dec. 31, 2005, was \$16,506,628. The Company's September 30 balance sheet also showed strained liquidity with \$11,307,513 in total current assets available to pay \$18,791,536 in total current liabilities. For the third quarter ended Sept. 30, 2006, the Company reported a \$2,514,834 net loss compared with \$7,897,455 of net income in the comparable quarter of 2005.

Intellectual Property: The Company has filed a number of applications for U.S. patents relating to its proprietary peptide manufacturing process and delivery technologies. Its most important U.S. manufacturing and delivery patents expire from 2016 to 2021. To date, nine U.S. patents have been issued, including five patents covering improvements in manufacturing technology, three patents covering oral delivery of peptides, and one patent covering the nasal calcitonin formulation. Other applications are pending. The Company also has made filings in selected foreign countries, and 46 foreign patents have been issued. [SEC Filing 10-K 03-16-06]

Description: Unigene Laboratories, Inc., a biopharmaceutical company, engages in the research, production, and delivery of peptide-related products for medical use.

Officers: Warren P. Levy (Pres., CEO & Dir.); Ronald S. Levy (EVP & Dir.); Jay Levy (Chair & Treas.); James P. Gilligan (VP-Dev't.); Nozer M. Mehta (VP-R&D); Paul P. Shields (VP-Mfg.); William J. Steinhauer (VP-Fin.); Allen Bloom (Dir.); J. Thomas August (Dir.); Robert F. Hendrickson (Dir.); Marvin L. Miller (Dir.); Bruce Morra (Dir.); Peter Slusser (Dir.)

Auditor: Grant Thornton LLP

Securities: Common Stock-Symbol UGNE.OB; OTC BB;
83,418,815 common shares outstanding as of March 1, 2006.

[Return to top](#)

**Prospector
Profile
06.0273**

World Heart Corp.

7799 Pardee Lane
Oakland, CA 94621
(510) 563-5000

NAICS		334510
Employees		117
Revenue	(mil)	\$11.65
Income	(mil)	(\$52.83)
Assets	(mil)	\$26.82
Liability	(mil)	\$6.11

(for the year ended 12/31/2005)

Category: Loss/Deficit

Event: On November 20, 2006, Nasdaq Stock Market notified World Heart Corp. that it does not comply with the minimum \$10 million stockholders' equity requirement for continued listing on Nasdaq. The Company had stockholders' equity of \$5,898,791 based on its SEC report for the quarter ended September 30. Nasdaq is reviewing the Company's eligibility for continued listing.

Intellectual Property: The Company has been granted 11 active United States patents for the Novacor LVAS and its associated subsystems. The Company has been granted one United States patent and a second patent application is pending for the Novacor II, and corresponding applications are also pending in Europe, Japan and Canada. The Transcutaneous Energy Transfer technology licensed to WorldHeart from the Ottawa Heart Institute intended to be incorporated in Novacor II has been patented in the US, Canada and the United Kingdom. As part of the MedQuest acquisition, WorldHeart now holds various patents and licenses to patents related to the WorldHeart rotary VAD and other potential future products. WorldHeart has ownership and/or exclusive licenses to 11 patents related to the MedQuest implantable blood pump technology. In addition, two patents are non-exclusively licensed related to control of rotary blood pumps. The Company has a number of trademarks, and it has federally registered several, including the WORLDHEART logo mark and the NOVACOR mark. [SEC Filing 10-K 03-27-06]

Description: World Heart Corp. is a medical devices firm focused on the sales, production, support and development of pulsatile ventricular assist devices.

Officers: C. Ian Ross (Chair); Jal S. Jassawalla (Pres., CEO & Dir.); A. Richard Juelis (VP & CFO); John F. Carlson (Dir.); William C. Garriock (Dir.); Robert J. Majteles (Dir.)

Auditor: PricewaterhouseCoopers LLP

Securities: Common Stock-Symbol WHRT; NasdaqNM;
55,479,549 common shares outstanding as of October 31, 2006.
3% unsecured convertible debentures due September 15, 2009.

[Return to top](#)

**Prospector
Profile
06.0274**

Zim Corporation

150 Isabella Street, Suite 150
Ottawa, Ontario, Canada K1S 1V7
(613) 727-1397

NAICS		517212
Employees		25
Revenue	(mil)	\$3.60
Income	(mil)	(\$3.39)
Assets	(mil)	\$2.32
Liability	(mil)	\$1.87
(for the year ended 3/31/2006)		

Category: Loss/Deficit

Event: ZIM Corp. reported that revenue for the three months ended Sept. 30, 2006, was \$580,913, compared with revenue of \$817,389 for the three months ended Sept. 30, 2005. Net loss for the three months ended Sept. 30, 2006, was \$369,991 as compared with \$368,720 for the three months ended Sept. 30, 2005. At Sept. 30, 2006, the Company's balance sheet showed \$2,121,914 in total assets, \$1,078,804 in total liabilities, and \$1,043,110 in total stockholders' equity.

Intellectual Property: Intellectual property does not represent a material part of the Company's assets or business strategy. The Company does not rely on patents or copyrights and, to the extent it maintains trade secrets, relies on confidentiality agreements to protect them from misappropriation. [SEC Filing 10-KSB 06-28-06]

Description: The Company is a provider of mobile messaging and data services. The Company use its technology and expertise to expand the use of the mobile phone beyond voice to include SMS messages and other content, such as ringtones and wallpapers.

Officers: Dr. Michael Cowpland (Pres., CEO & Dir.); Jennifer North (CFO); Roberto Campagna (VP-Sales); Steven Houck (Dir.); Charles Saikaley (Dir.); James Stechyson (Dir.); Donald Gibbs (Dir.)

Auditor: Raymond Chabot Grant Thornton LLP

Securities: Common Stock-Symbol ZIMCF.OB; OTC BB; 69,561,569 common shares outstanding as of June 8, 2006.

[Return to top](#)